Proton pump inhibitor (PPI) use leads to hypergastrinaemia, which has been associated with gastrointestinal neoplasia. We evaluated the association between PPI use and risk of gastric cancer using ...

A new study provides reassurance about the long-term safety of proton pump inhibitors (PPIs) and histamine-2 receptor antagonist (H2RA) use in older adults, finding no increased risk for dementia or ...

The use of omeprazole or pantoprazole in patients with knee osteoarthritis (OA) was associated with a higher risk of knee replacement (KR) surgery compared with histamine-2 receptor antagonist (H2RA) ...

In patients with Barrett’s esophagus (BE), acid suppression with proton pump inhibitors (PPIs) and histamine, -receptor antagonists (H2RA) reduced the risk of progression to esophageal adenocarcinoma ...

Proton pump inhibitors (PPIs) represent a widely used class of medications for the treatment of acid-related gastrointestinal conditions worldwide. Prior studies have suggested that PPI use is ...

CAVHANZA™ (nilotinib) Orally Disintegrating Tablets: A New, FDA-approved Treatment Offering PPI and H2RA Flexibility for Ph+ CML Patients1 Cycle Pharmaceuticals (Cycle) announces the FDA approval of ...

Please provide your email address to receive an email when new articles are posted on . Proton pump inhibitors with histamine 2 receptor antagonists reduced all-cause mortality in patients with ...